|Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment|
N Müller, D Krause, S Dehning, R Musil, R Schennach-Wolff, ...
Schizophrenia research 121 (1-3), 118-124, 2010
|Weight gain and antipsychotics: a drug safety review|
R Musil, M Obermeier, P Russ, M Hamerle
Expert opinion on drug safety 14 (1), 73-96, 2015
|Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression—no influence of celecoxib treatment|
R Musil, MJ Schwarz, M Riedel, S Dehning, A Cerovecki, I Spellmann, ...
Journal of affective disorders 134 (1-3), 217-225, 2011
|Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations|
A Cerovecki, R Musil, A Klimke, F Seemüller, E Haen, R Schennach, ...
CNS drugs 27 (7), 545-572, 2013
|Outcomes of 1014 naturalistically treated inpatients with major depressive episode|
F Seemüller, M Riedel, M Obermeier, M Bauer, M Adli, K Kronmüller, ...
European Neuropsychopharmacology 20 (5), 346-355, 2010
|Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an …|
G Arteaga-Henríquez, MS Simon, B Burger, E Weidinger, A Wijkhuijs, ...
Frontiers in psychiatry 10, 458, 2019
|Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms|
M Riedel, N Müller, M Strassnig, I Spellmann, RR Engel, R Musil, ...
European archives of psychiatry and clinical neuroscience 255 (6), 432-437, 2005
|Neurocognition and its influencing factors in the treatment of schizophrenia—effects of aripiprazole, olanzapine, quetiapine and risperidone|
M Riedel, R Schennach‐Wolff, R Musil, S Dehning, A Cerovecki, ...
Human Psychopharmacology: Clinical and Experimental 25 (2), 116-125, 2010
|Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis|
BB Barton, F Segger, K Fischer, M Obermeier, R Musil
Expert opinion on drug safety 19 (3), 295-314, 2020
|Treatment response in first-episode schizophrenia|
R Schennach, M Riedel, R Musil, HJ Möller
Clinical Psychopharmacology and Neuroscience 10 (2), 78, 2012
|Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients|
I Spellmann, D Rujescu, R Musil, A Mayr, I Giegling, J Genius, P Zill, ...
Journal of psychiatric research 45 (2), 234-241, 2011
|Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia|
M Riedel, N Müller, I Spellmann, RR Engel, R Musil, R Valdevit, ...
European archives of psychiatry and clinical neuroscience 257 (7), 402-412, 2007
|Efficacy of acupuncture for primary insomnia: a randomized controlled clinical trial|
J Guo, LP Wang, CZ Liu, J Zhang, GL Wang, JH Yi, JL Cheng, R Musil
Deutsche Zeitschrift für Akupunktur 57 (4), 31-32, 2014
|Review and consensus on pharmacogenomic testing in psychiatry|
CA Bousman, SA Bengesser, KJ Aitchison, AT Amare, H Aschauer, ...
Pharmacopsychiatry 54 (01), 5-17, 2021
|Effect of aripiprazole on cognition in the treatment of patients with schizophrenia|
M Riedel, I Spellmann, R Schennach-Wolff, R Musil, S Dehning, ...
Pharmacopsychiatry 43 (02), 50-57, 2010
|SNAP-25 gene polymorphisms and weight gain in schizophrenic patients|
R Musil, I Spellmann, M Riedel, S Dehning, A Douhet, K Maino, P Zill, ...
Journal of psychiatric research 42 (12), 963-970, 2008
|A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome|
S Dehning, N Müller, J Matz, A Bender, I Kerle, J Benninghoff, R Musil, ...
Psychiatric genetics 20 (1), 35-38, 2010
|Functional outcomes in schizophrenia: employment status as a metric of treatment outcome|
R Schennach, R Musil, HJ Möller, M Riedel
Current psychiatry reports 14 (3), 229-236, 2012
|Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors|
F Seemüller, S Meier, M Obermeier, R Musil, M Bauer, M Adli, ...
European archives of psychiatry and clinical neuroscience 264 (7), 567-575, 2014
|Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics|
I Spellmann, N Müller, R Musil, P Zill, A Douhet, S Dehning, A Cerovecki, ...
European archives of psychiatry and clinical neuroscience 258 (6), 335-344, 2008